معرفی
Bernard Flynn is an Associate Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University, affiliated with the Monash Institute of Pharmaceutical Sciences. He specializes in Medicinal Chemistry, focusing on drug discovery, cardiovascular drugs, and combinatorial chemistry. His research projects include developing gastrointestinal-restricted ALK5 inhibitors for intestinal fibrosis and drug discovery platforms targeting polynucleotides.
Research Interests: Dr. Flynn’s work spans medicinal chemistry, synthetic methodology, and chemical biology. Key areas include anticancer natural product synthesis, GPCR studies, and sphingolipid metabolism in cardiovascular diseases. His contributions align with UN Sustainable Development Goals, emphasizing health and innovation.
Publications: Recent works highlight advancements in sphingolipid signaling, cardiac fibrosis mechanisms, and drug delivery systems. His articles often address synthetic chemistry challenges and translational applications.
Awards: Recipient of the ACT Young Tall Poppy Science Award (2003), Australian Research Fellowship (1998), and multiple industry awards. These recognize his contributions to medicinal chemistry and drug discovery.
Grants & Patents: Principal Investigator on projects funded by the National Foundation for Medical Research and Innovation and the Medical Research Future Fund. Holds patents in drug delivery systems, GPCR antagonists, and synthetic methodologies.
Labs/Teams: Active in Monash’s pharmaceutical research groups, collaborating globally on projects like nanostar drug carriers and sphingolipid-targeted therapies.
